The Sunshine Reporter

Obesity Overview

Obesity is a multi-factorial disorder, which is often associated with many other significant diseases such as diabetes, hypertension and other cardiovascular diseases, osteoarthritis and certain cancers. The management of obesity will therefore require a comprehensive range of strategies focussing on those with existing weight problems and also on those at high risk of developing obesity. Hence, prevention of obesity during childhood should be considered a priority, as there is a risk of persistence to adulthood. Obesity can be described as the “New World Syndrome”. Its prevalence is on continuous rise in all age groups of many of the developed countries in the world.

“Obesity Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obesity Market. 

The Obesity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Obesity Pipeline Report:

• Companies across the globe are diligently working toward developing novel Obesity treatment therapies with a considerable amount of success over the years. Obesity Key players such as – Sciwind Biosciences, BioRestorative Therapies, Takeda, Daewoong Pharmaceutical, ERX Pharmaceuticals, Aardvark Therapeutics, Eli Lily & Company, Novo Nordisk, and others, are developing therapies for the Obesity treatment 

• Obesity Emerging therapies such as – XW017, Thermostem, SCO094, DWP 306001, ERX1000, ARD101, LY3502970, XW003, Tirzepatide, Semaglutide Oral, and others are expected to have a significant impact on the Obesity market in the coming years.   
• In April 2021, Eli Lily & Company initiated Randomized, Double-Blind, Placebo Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity. The study will continue until approximately 52 weeks after the last participant is randomized.

Obesity Pipeline Therapeutics Assessment

• Obesity Assessment by Product Type
• Obesity By Stage and Product Type
• Obesity Assessment by Route of Administration
• Obesity By Stage and Route of Administration
• Obesity Assessment by Molecule Type
• Obesity by Stage and Molecule Type 

DelveInsight’s Obesity Report covers around 120+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Obesity Drugs Under Different Phases of Clinical Development Include:

• XW017: Sciwind Biosciences
• Thermostem: BioRestorative Therapies
• SCO094: Takeda
• DWP 306001: Daewoong Pharmaceutical
• ERX1000: ERX Pharmaceuticals
• ARD101: Aardvark Therapeutics
• LY3502970: Eli Lily &Company
• XW003: Sciwind Biosciences
• Tirzepatide: Eli Lily &Company
• Semaglutide Oral: Novo Nordisk 

Get a Free Sample PDF Report to know more about Obesity Pipeline Assessment

Obesity Pipeline Analysis:

The Obesity pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Obesity treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
• Obesity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Obesity product details are provided in the report. Download the Obesity pipeline report to learn more about the emerging Obesity therapies

Obesity Pipeline Market Drivers

• Rising incidence of Obesity
• Awareness on Obesity Related problem
• Demand for New and Effective Drugs

Obesity Pipeline Market Barriers

• High cost associated with the treatment of obesity

Scope of Obesity Pipeline Drug Insight    

• Coverage: Global
• Key Obesity Companies: Sciwind Biosciences, BioRestorative Therapies, Takeda, Daewoong Pharmaceutical, ERX Pharmaceuticals, Aardvark Therapeutics, Eli Lily & Company, Novo Nordisk, and others
• Key Obesity Therapies: XW017, Thermostem, SCO094, DWP 306001, ERX1000, ARD101, LY3502970, XW003, Tirzepatide, Semaglutide Oral, and others
• Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
• Obesity Market Dynamics:  Obesity market drivers and Obesity market barriers 

Request for Sample PDF Report for Obesity Pipeline Assessment and clinical trials 

Table of Contents

Download Sample PDF Report to know more about Obesity drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com